ACADIA Pharmaceuticals' (ACAD) CEO Steve Davis on Q3 2017 Results - Earnings Call Transcript [Seeking Alpha]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Seeking Alpha
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Q3 2017 Results Conference Call November 07, 2017 05:00 AM ET Executives Lisa Barthelemy - Senior Director of IR Steve Davis - President and CEO Todd Young - EVP and CFO Michael Yang - EVP and CCO Dr. Serge Stankovic - EVP and Head, R&D Analysts Tazeen Ahmad - BofA Merrill Lynch Charles Duncan - Piper Jaffray Jason Butler - JMP Securities Cory Kasimov - JP Morgan Chase Salveen Richter - Goldman Sachs Alexandria Huynh - Cowen and Company Paul Matteis - Leerink Partners Operator Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals Third Quarter 2017 Financial Results Conference Call. My name is April, and I will be your coordinator for today. [Operation Instructions] I would now like to turn the presentation over to Lisa Barthelemy, Senior Director of Investor Relations at ACADIA. Please proceed. Lisa Barthelemy Thank you, April. Good afternoon, and welcome to ACADIA's Third Q
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Acadia Pharmaceuticals Inc. (ACAD) InvestigationAccesswire
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $25.00. They now have an "overweight" rating on the stock.MarketBeat
ACAD
Earnings
- 2/27/24 - Miss
ACAD
Sec Filings
- 3/27/24 - Form 4
- 3/27/24 - Form 4
- 3/27/24 - Form 4
- ACAD's page on the SEC website